BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma. Clonidine Lauriad® uses the innovative muco-adhesive technology validated with Loramyc® and more recently with acyclovir Lauriad®…

Read the rest here: 
BioAlliance Pharma : Entry Into Clinical Phase: Clonidine Lauriad(R) Into Phase II And AMEPTM Into Phase I

You may also like:

• Arno Therapeutics Announces Poster Presentation At ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity Of AR-42
• Ouroboros Medical Inc. Establishes European Approval And Awarded 2009 Spine Technology Summit Award
• Ten Million Deaths And 1 Million New HIV Infections Could Be Averted If Countries Meet HIV Treatment Targets
• VIVUS Announces FDA Acceptance Of Qnexa(R) New Drug Application For Treatment Of Obesity
• Tioga Pharmaceuticals, Inc. Raises $18 Million To Fund Phase 3 Clinical Trial In Irritable Bowel Syndrome
• Bioheart Launches First US FDA Approved Clinical Trial That Tests Gene-Modified Stem Cell Therapy In Patients With Congestive Heart Failure
• New Study Demonstrates Novel Use Of Metabolic Imaging To Locate Sperm In Infertile Men
• Seattle Genetics And Millennium Announce Initiation Of Phase I Combination Clinical Trial Of Brentuximab Vedotin For Front-line Hodgkin Lymphoma
• Data From TNFerade(TM) Esophageal Cancer Study Presented At 2010 ASCO Gastrointestinal Cancer Symposium
• Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary Endpoints